MedTrace Logo

A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors

NCT05615974 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 139

Last updated 2024-12-19

No results posted yet for this study

Summary

This study is to assess the safety and tolerability, obtain Maximum Tolerated Dose (MTD) and/or the recommended phase 2 dose (RP2D) of LM-101 as a single agent or in combination in patients with advanced malignant tumors

Conditions

  • Malignant Tumors

Interventions

DRUG

LM101

Administered intravenously

DRUG

Toripalimab

Administered intravenously

DRUG

Rituximab

Administered intravenously

Sponsors & Collaborators

  • LaNova Medicines Limited

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-11
Primary Completion
2027-01-11
Completion
2028-01-11

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05615974 on ClinicalTrials.gov